• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Here's What to Expect From Biotech in 2023

After a cruel 2022, here are my views on this high-beta sector as we head into the new year.
By BRET JENSEN
Dec 02, 2022 | 01:30 PM EST
Stocks quotes in this article: XBI, NVAX, PFE, AZN, MRNA, HZNP

We kicked off trading in December Thursday as 2022 rapidly comes to a close. The market has not been kind to the biotech sector in 2022 a statement that can be made about most areas of equities in what has been cruel year for investors.

So, as we look to turn the page on 2022, what is ahead for biotech in the new year? Here are a few things I think about the sector in 2023.

As I noted in my column Wednesday, it would not surprise me at all if stocks got off to a rough start in the first half of 2023. Rising interest rates are having painful effects on many parts of the economy, and a recession at some point in the coming year would appear to have a high probability. That said, I think the lows the biotech sector established in mid-June of this year will hold throughout 2023.

There are several reasons I believe this.

The biotech sector, represented by the SPDR S&P Biotech ETF (XBI) , bottomed at the same level that has been a floor for the sector for many years (see chart above).

Second, the fizz from the Covid plays that powered the sector, starting after the lockdown lows in 2020 through the first part of 2021, has been completely burned off. One can take a look at vaccine-play Novavax (NVAX) to see how volatile that move was:

What's more, there was a massive amount of new supply that came on the market in 2021 thanks to a boom in biotech IPOs and the SPAC craze, powered by the easy money policies of the Federal Reserve at the time. However, as rates have risen, that source of new supply has slowed to a crawl, which is supportive of currently public firms.

I also think M&A in the sector will pick up noticeably after being largely dormant over the past few years. Big Pharma is flush with cash and names such as Pfizer (PFE) , AztraZeneca (AZN) and Moderna (MRNA) need to continue to deploy some of their Covid lucre to expand their pipelines and product portfolios as vaccine revenues are ebbing. There has been a lot of speculation recently about the possible buyout of Horizon Therapeutics (HZNP) , which would be a north of a $25 billion purchase.

One last word and I continue to stress this caveat. Investors should peruse the balance sheets of any potential small and midcap biotech investments before establishing any new stakes. Financing has become harder to come by over the last year as the credit markets feel the impact of monetary tightening. I am only looking at names that are either already profitable or have 24-36 months of cash on hand for their projected burn rates.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen had no positions in any securities mentioned.

TAGS: Growth Investing | Mergers and Acquisitions | Investing | Markets | Small Cap | Stocks | Biotechnology | U.S. Equity

More from Stocks

Bearish Bets: 3 Stocks You Should Consider Shorting This Week

Bob Lang
Jun 4, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

The Word Is, 'Lexicon' Is Worth a Trade

Bret Jensen
Jun 4, 2023 7:00 AM EDT

Here's an options play on this small pharma name that just scored an FDA win.

As the Market Shifts, So Should Your Strategy

James "Rev Shark" DePorre
Jun 3, 2023 11:50 AM EDT

Let's look a how to adjust trading techniques to fit the changes in the market.

Market's Frothy With a Side of FOMO

James "Rev Shark" DePorre
Jun 2, 2023 4:41 PM EDT

The small caps and the Dow finally host the party on Wall Street. But will this broadening action continue?

This Is Still My 'Preferred' Style of Investing

Jim Collins
Jun 2, 2023 2:00 PM EDT

Let's look at some whopping returns for VLYPO and two others to dive into.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • 12:07 PM EDT STEPHEN GUILFOYLE

    Selling Some of This Surging AI-Related Stock

    This isn't the only name in the Stocks Under $10 p...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login